A pilot study into the effects of the CB1 cannabinoid receptor agonist, WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats

Anushka V. Goonawardena, Andrea Plano, Lianne Robinson, Bettina Platt, Robert E. Hampson, Gernot Riedel

Research output: Contribution to journalArticle

Abstract

The plant cannabinoid Δ9-tetrahydrocannabinol and the endocannabinoid anandamide increase the amount of sleep via a CB1 receptor mediated mechanism. Here, we explored the use of a novel electroencephalogram (EEG) recording device based on wireless EEG microchip technology (Neurologger) in freely-moving rats, and its utility in experiments of cannabinoids-induced alterations of EEG/vigilance stages. EEG was recorded through epidural electrodes placed above pre-frontal and parietal cortex (overlaying the dorsal hippocampus). As cannabinoids, we acutely administered the full synthetic CB1 receptor agonist, WIN55,212-2 (1 mg/kg), and the antagonist/inverse agonist, AM251 (2 mg/kg), either alone or together through the intraperitoneal route. WIN55,212-2 increased the total amount of NREM sleep and the length of each NREM bout, but this was unlikely due to CB1 receptor activation since it was not prevented by AM251. However, WIN55,212-2 also lowered overall EEG spectral power especially in theta and alpha frequency bands during wakefulness and NREM sleep, and this effect was reversed by AM251. The antagonist/inverse agonist caused no sleep alterations by itself and moderately increased spectral power in Theta, alpha and beta frequency bands during NREM sleep when administered on its own. Implications of endocannabinoid modulation of the sleep-wake cycle and its possible interactions with other transmitter systems are considered.
Original languageEnglish
Article number178469
Number of pages7
JournalSleep Disorders
Volume2011
DOIs
Publication statusPublished - 1 Dec 2011

Fingerprint

Cannabinoid Receptor Agonists
Sleep
Electroencephalography
Cannabinoid Receptor CB1
Cannabinoids
Endocannabinoids
Artificial Receptors
Parietal Lobe
Dronabinol
Wakefulness
Frontal Lobe
AM 251
Hippocampus
Electrodes
Technology
Equipment and Supplies

Keywords

  • EEG cannabinoids wireless

Cite this

A pilot study into the effects of the CB1 cannabinoid receptor agonist, WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats. / Goonawardena, Anushka V.; Plano, Andrea; Robinson, Lianne; Platt, Bettina; Hampson, Robert E.; Riedel, Gernot.

In: Sleep Disorders, Vol. 2011, 178469, 01.12.2011.

Research output: Contribution to journalArticle

@article{b7fa8a49a98d4cc5b97a5d052f9c75ad,
title = "A pilot study into the effects of the CB1 cannabinoid receptor agonist, WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats",
abstract = "The plant cannabinoid Δ9-tetrahydrocannabinol and the endocannabinoid anandamide increase the amount of sleep via a CB1 receptor mediated mechanism. Here, we explored the use of a novel electroencephalogram (EEG) recording device based on wireless EEG microchip technology (Neurologger) in freely-moving rats, and its utility in experiments of cannabinoids-induced alterations of EEG/vigilance stages. EEG was recorded through epidural electrodes placed above pre-frontal and parietal cortex (overlaying the dorsal hippocampus). As cannabinoids, we acutely administered the full synthetic CB1 receptor agonist, WIN55,212-2 (1 mg/kg), and the antagonist/inverse agonist, AM251 (2 mg/kg), either alone or together through the intraperitoneal route. WIN55,212-2 increased the total amount of NREM sleep and the length of each NREM bout, but this was unlikely due to CB1 receptor activation since it was not prevented by AM251. However, WIN55,212-2 also lowered overall EEG spectral power especially in theta and alpha frequency bands during wakefulness and NREM sleep, and this effect was reversed by AM251. The antagonist/inverse agonist caused no sleep alterations by itself and moderately increased spectral power in Theta, alpha and beta frequency bands during NREM sleep when administered on its own. Implications of endocannabinoid modulation of the sleep-wake cycle and its possible interactions with other transmitter systems are considered.",
keywords = "EEG cannabinoids wireless",
author = "Goonawardena, {Anushka V.} and Andrea Plano and Lianne Robinson and Bettina Platt and Hampson, {Robert E.} and Gernot Riedel",
year = "2011",
month = "12",
day = "1",
doi = "10.1155/2011/178469",
language = "English",
volume = "2011",
journal = "Sleep Disorders",

}

TY - JOUR

T1 - A pilot study into the effects of the CB1 cannabinoid receptor agonist, WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats

AU - Goonawardena, Anushka V.

AU - Plano, Andrea

AU - Robinson, Lianne

AU - Platt, Bettina

AU - Hampson, Robert E.

AU - Riedel, Gernot

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The plant cannabinoid Δ9-tetrahydrocannabinol and the endocannabinoid anandamide increase the amount of sleep via a CB1 receptor mediated mechanism. Here, we explored the use of a novel electroencephalogram (EEG) recording device based on wireless EEG microchip technology (Neurologger) in freely-moving rats, and its utility in experiments of cannabinoids-induced alterations of EEG/vigilance stages. EEG was recorded through epidural electrodes placed above pre-frontal and parietal cortex (overlaying the dorsal hippocampus). As cannabinoids, we acutely administered the full synthetic CB1 receptor agonist, WIN55,212-2 (1 mg/kg), and the antagonist/inverse agonist, AM251 (2 mg/kg), either alone or together through the intraperitoneal route. WIN55,212-2 increased the total amount of NREM sleep and the length of each NREM bout, but this was unlikely due to CB1 receptor activation since it was not prevented by AM251. However, WIN55,212-2 also lowered overall EEG spectral power especially in theta and alpha frequency bands during wakefulness and NREM sleep, and this effect was reversed by AM251. The antagonist/inverse agonist caused no sleep alterations by itself and moderately increased spectral power in Theta, alpha and beta frequency bands during NREM sleep when administered on its own. Implications of endocannabinoid modulation of the sleep-wake cycle and its possible interactions with other transmitter systems are considered.

AB - The plant cannabinoid Δ9-tetrahydrocannabinol and the endocannabinoid anandamide increase the amount of sleep via a CB1 receptor mediated mechanism. Here, we explored the use of a novel electroencephalogram (EEG) recording device based on wireless EEG microchip technology (Neurologger) in freely-moving rats, and its utility in experiments of cannabinoids-induced alterations of EEG/vigilance stages. EEG was recorded through epidural electrodes placed above pre-frontal and parietal cortex (overlaying the dorsal hippocampus). As cannabinoids, we acutely administered the full synthetic CB1 receptor agonist, WIN55,212-2 (1 mg/kg), and the antagonist/inverse agonist, AM251 (2 mg/kg), either alone or together through the intraperitoneal route. WIN55,212-2 increased the total amount of NREM sleep and the length of each NREM bout, but this was unlikely due to CB1 receptor activation since it was not prevented by AM251. However, WIN55,212-2 also lowered overall EEG spectral power especially in theta and alpha frequency bands during wakefulness and NREM sleep, and this effect was reversed by AM251. The antagonist/inverse agonist caused no sleep alterations by itself and moderately increased spectral power in Theta, alpha and beta frequency bands during NREM sleep when administered on its own. Implications of endocannabinoid modulation of the sleep-wake cycle and its possible interactions with other transmitter systems are considered.

KW - EEG cannabinoids wireless

U2 - 10.1155/2011/178469

DO - 10.1155/2011/178469

M3 - Article

VL - 2011

JO - Sleep Disorders

JF - Sleep Disorders

M1 - 178469

ER -